Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Sanofi (SNY) Receivables Refunds (2016 - 2025)

Sanofi's Receivables Refunds history spans 9 years, with the latest figure at $462.1 million for Q4 2025.

  • For Q4 2025, Receivables Refunds fell 40.27% year-over-year to $462.1 million; the TTM value through Dec 2025 reached $462.1 million, down 40.27%, while the annual FY2025 figure was $448.5 million, 42.76% down from the prior year.
  • Receivables Refunds for Q4 2025 was $462.1 million at Sanofi, down from $773.7 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $773.7 million in Q4 2024 and bottomed at $381.6 million in Q4 2022.
  • The 5-year median for Receivables Refunds is $462.1 million (2025), against an average of $547.6 million.
  • The largest annual shift saw Receivables Refunds crashed 51.39% in 2021 before it soared 83.9% in 2024.
  • A 5-year view of Receivables Refunds shows it stood at $700.1 million in 2021, then plummeted by 45.5% to $381.6 million in 2022, then grew by 10.25% to $420.7 million in 2023, then skyrocketed by 83.9% to $773.7 million in 2024, then crashed by 40.27% to $462.1 million in 2025.
  • Per Business Quant, the three most recent readings for SNY's Receivables Refunds are $462.1 million (Q4 2025), $773.7 million (Q4 2024), and $420.7 million (Q4 2023).